Moderna, Merck Say mRNA Melanoma Vaccine Succeeded in Phase 3
Moderna and Merck say their personalized mRNA cancer vaccine succeeded in a Phase 3 melanoma trial — a first for the mRNA platform in cancer.
Topic
Pembrolizumab
Topic
Pembrolizumab
Moderna–Merck Melanoma Combo Cuts Spread Risk at Five Years
Moderna and Merck report their mRNA cancer vaccine–pembrolizumab combination cut the risk of melanoma spread at five years, a dur…
mRNA Cancer Vaccine Plus Keytruda Boosts Melanoma Survival
An mRNA cancer vaccine combined with Keytruda sharply improved survival in melanoma patients, UCHealth trial results show, advanc…